{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-008288","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.672841+00:00","generated_at":"2026-05-16T20:20:35.405455+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xenetic Biosciences Q3 net loss ~$0.5M, revenue up 67% to $1.0M; cash extended by $3.9M offering","bullets":["Net loss of approximately $0.5M for Q3 2025; revenue rose 67% YoY to $1.0M on higher Takeda royalty payments.","R&D expenses increased 105.6% to $0.8M due to manufacturing and pre-clinical work; G&A rose 9.3% to $0.8M on legal costs.","Cash at Sept 30, 2025 was ~$4.1M; subsequent October 2025 offering added ~$3.9M net proceeds, extending runway.","DNase I program advancing toward IND submission and Phase 1 for pancreatic and solid tumors; preclinical studies ongoing.","PeriNess agreement for investigator-initiated studies in Israeli centers under regulatory approval process."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-008288","json":"https://secwatch.observer/filing/0001683168-25-008288.json","markdown":"https://secwatch.observer/filing/0001683168-25-008288.md","text":"https://secwatch.observer/filing/0001683168-25-008288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825008288/0001683168-25-008288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316825008288/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:20:35.405455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}